01:01 AM EDT, 10/06/2026 (MT Newswires) -- BofA Global Research expects AstraZeneca (AZN.L, AZN.ST) to deliver "in-line" third-quarter results and affirm its full-year 2026 guidance amid the sustained performance of some of the biopharmaceutical company's cancer treatments. "Key factors within the Q: 1) continued robust sales growth for key franchises with Tagrisso +6% YoY, Imfinzi +c24% YoY, Enhertu +c54% YoY; 2) Farxiga impact from April 26 US generics and VBP impact from Feb, with sales at c$1.6bn, -c26% YoY, marginally below consensus; 3) Japan price cuts in April for Calquence and Farxiga; 4) margin of c33.9% (+c110bp YoY), in line with consensus; 5) slightly worse finance expense vs consensus, in line with comments for 2H above 1H; 6) not expecting FY26 guide change, but do expect FY27E margin debate to kick off again," according to a Monday note. Against this backdrop, the research firm projects a 5% year-over-year increase in AstraZeneca's third-quarter total group revenue to $15.9 billion and a 9% rise in EPS to $2.60, both consistent with market expectations. Looking ahead, analysts forecast management to target mid-single-digit to high-single-digit revenue growth for 2027 alongside low-double-digit EPS growth. Despite ongoing investor debate about potential margin drag on EPS, the research firm sees this concern offset by a "better" sales outlook, modeling 9% revenue growth for the year driven by key cancer drugs and anticipated $1.4 billion from upcoming pipeline launches. Ahead of the company's earnings report scheduled for Oct. 30, BofA maintained the stock's buy rating, with a price objective of 165 pounds sterling.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.